Compare NABL & BHVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NABL | BHVN |
|---|---|---|
| Founded | 2000 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.1B |
| IPO Year | N/A | 2017 |
| Metric | NABL | BHVN |
|---|---|---|
| Price | $7.60 | $11.54 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 4 | 16 |
| Target Price | $9.31 | ★ $29.79 |
| AVG Volume (30 Days) | 848.8K | ★ 3.5M |
| Earning Date | 11-06-2025 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $497,665,000.00 | N/A |
| Revenue This Year | $11.18 | N/A |
| Revenue Next Year | $8.73 | $2,219.74 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 8.65 | N/A |
| 52 Week Low | $6.07 | $7.48 |
| 52 Week High | $10.41 | $44.28 |
| Indicator | NABL | BHVN |
|---|---|---|
| Relative Strength Index (RSI) | 52.50 | 57.02 |
| Support Level | $7.49 | $8.29 |
| Resistance Level | $7.74 | $11.71 |
| Average True Range (ATR) | 0.19 | 0.72 |
| MACD | 0.06 | 0.47 |
| Stochastic Oscillator | 79.23 | 95.32 |
N-able Inc is a provider of cloud-based software solutions for managed service providers (MSPs), enabling them to support digital transformation and growth for small and medium-sized enterprises. With a flexible technology platform and powerful integrations, N-able makes it easy for MSPs to monitor, manage, and protect their end-customer systems, data, and networks. The company's growing portfolio of management, security, automation, and data protection solutions is built for IT services management professionals. Geographically, the majority of revenue is from the United States. The company also has a presence in the United Kingdom and all other International regions.
Biohaven Ltd is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of life-changing treatments in key therapeutic areas, including immunology, neuroscience, and oncology. Its product pipeline includes Glutamate, Myostatin, Ion channels, Inflammation & Immunology, and Oncology. The company's products target diseases such as neuromuscular and metabolic diseases, antibody-drug conjugates for cancer, obsessive-compulsive disorder, and others.